James Thrasher, MD, FACE

Curriculum Vitae
11400 Huron Ln.
Little Rock, Arkansas 72211

SPECIALTY

Endocrinology, Diabetes and Metabolism. .

EDUCATION

Undergraduate School: Arkansas State University, Jonesboro, Arkansas 72467
Degree: B.S. Major: Zoology Minor: Chemistry Graduation: August 1991

Graduate School: Arkansas State University, Jonesboro, Arkansas 72467
Degree: None Major: Cellular and Molecular Biology

Medical School: University of Arkansas for Medical Sciences, College of Medicine, 4301 West Markham Street, Little Rock, Arkansas 72202
Degree: M.D. Graduation: May 18, 1996

Intern in Internal Medicine: UAMS Medical Center, 4301 West Markham Street, Little Rock, Arkansas 72202 and John McClellan Memorial Veterans hospital, 4300 West 7th Street, Little Rock, Arkansas 72202. June 1 1996 to May 31, 1997

Resident in Internal Medicine: UAMS Medical Center, 4301 West Markham Street Little Rock, Arkansas 72202, and John McClellan Memorial Veterans Hospital, 4300 West 7th Street, Little Rock, Arkansas 72202 June 1, 1997 to May 31, 1999

PROFESSIONAL HISTORY

June 1999-August 2002	National Health Service Corps: White River Medical Center, Batesville, Arkansas Director of Diabetes Clinic, Carson City Hospital, Carson City, Michigan and Chief of Medicine, Director of Diabetes Clinic, Director of Cardiopulmonary Services, Sheridan Community Hospital, Sheridan Michigan
September 2003-2013	Medical Director, Care Network Home Health Little Rock, Arkansas
September 2002-Present	CEO, President and Endocrinologist Arkansas Diabetes and Endocrinology Center Little Rock, Arkansas

June 2004-Present	CEO, President and Research Physician Medical Investigations, Inc. Little Rock, Arkansas

MEMBERSHIP AND COMMITTEES

American College of Endocrinology
American Association of Clinical Endocrinologists
American Diabetes Association

FELLOWSHIPS AND AWARDS

Fellow of the American College of Endocrinology. May 16, 2009-Current

Top Doctors 2020 (Endocrinology) Arkansas Life magazine 2020

Diabetes Physician Recognition Program, American Diabetes Association and National Committee for Quality Assurance. April 3, 2007-2010. 7 November 2016-2019. December 2019-2022

"America's Top Physicians" Endocrinology, Diabetes & Metabolism., 2007. Consumers Research Council of America

Center of Excellence, Medtronic. 2009

Center of Excellence, Sanofi, 2012

PUBLICATIONS

Thrasher JR, Talley JD. Syncope and Aortic Stenosis: Clues to Diagnosis and Pathophysiology. J Ark Med Soc. 1996 September; 93 (4): 1991-3

Thrasher J, Daniels K, Patel S, Whetteckey J. Randomized, Placebo-Controlled, Double-Blind, 24-Week Study of Linagliptin 5 Mg/Day in Black/African American Patients with Type 2 Diabetes. Oral presentation, American Association of Clinical Endocrinologists 21st Annual Scientific and Clinical Congress. May 24, 2012 Philadelphia, PA. Abstract published in the AACE Annual Meeting Syllabus, 2012.

Thrasher J, Daniels K, Patel S, Whetteckey J. Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin. Expert Opin Pharmacother 2012;13:2443-52

Thrasher J, Daniels K, Patel S, Whetteckey J, Woerle HJ. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study. Endocrine Practice. 2014 May 1;20(5):412-20

Timothy S. Bailey, Satish Garg, James Thrasher, John B. Welsh, Pratik Agrawal, Scott W. Lee. ASPIRE Clinical Trial Versus CareLink Real-world Experiences With Insulin Pump Suspension For Mitigation Of Iatrogenic Hypoglycemia. Poster presented at AACE 2014: 23rd Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists. May 14-18, 2014, Las Vegas, NV. Abstract published in the AACE Annual Meeting Syllabus, 2014.

James Thrasher, David Kountz, Susanne Crowe, Maximilian von Eynatten, Margaret Wooddell. "Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes (T2D): Pooled Analysis from 8 Randomized, Placebo Controlled Phase 3 Trials. Poster presented at AACE 2014: 23rd Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists. May 14-18, 2014, Las Vegas, NV. Abstract published in the AACE Annual Meeting Syllabus, 2014.

Ruth S. Weinstock, Richard M. Bergenstal, Satish Garg, Timothy S. Bailey, James Thrasher, Meng Mao, John Shin, ASPIRE In-home Study Group. Reduction in Hypoglycemia Across a Range of Definitions in the ASPIRE In-Home Study. Poster presented at ADA 2014: 74th Scientific Sessions of the American Diabetes Association. June 13-17, 2014, San Francisco, CA. Abstract published in Diabetes 2014 63 SUPPL. 1(A240)

Ram Weiss, Timothy S. Bailey, Frank L. Schwartz, Satish Garg, Andrew J. Ahmann, James Thrasher, Suiying Huang, Scott W. Lee, ASPIRE In-Home Study Group. Time Spent (%) in Hypoglycemia Following Automatic Threshold Suspend Activation in the ASPIRE In-Home Study. Poster presented at ADA 2014: 74th Scientific Sessions of the American Diabetes Association. June 13-17, 2014, San Francisco, CA. Abstract published in Diabetes 2014 63 SUPPL. 1 (A241)

Ram Weiss, Robert H. Slover, Frank L. Schwartz, James Thrasher, John B. Welsh, Meng Mao, Francine R. Kaufman. Effects of Automatic Insulin Pump Interruption on the Timing and Rate of Nocturnal Hypoglycemic Events in the ASPIRE In-Home Study. Oral presentation 72 at ISPAD 2014: 40th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes, September 3-6, Toronto, Canada. Abstract to be published in Pediatric Diabetes.

David Klonoff, Andrew Ahmann, Satish Garg, Robert H. Slover, Timothy S. Bailey, Bruce Bode, James Thrasher, Ronald Brazg, Frank L. Schwartz, Meng Mao, Ram Weiss, ASPIRE In-Home Study Group. Effects of automatic insulin pump interruption and bedtime glucose levels on nocturnal hypoglycemic events in the ASPIRE In-Home Study. Poster at EASD 2014: 50th Annual Meeting of the European Association for the Study of Diabetes, 15-19 September 2014, Vienna, Austria. Abstract to be published in Diabetologia.

Ram Weiss, Bruce Bode, Timothy S. Bailey, Frank L. Schwartz, Ronald Brazg, Richard Bergenstal, James Thrasher, Ruth Weinstock, Andrew Ahmann, David Klonoff, Robert H. Slover, Satish Garg, John B. Welsh, Meng Mao, ASPIRE In-Home Study Group. Effects of automatic insulin pump interruption on duration and weekly rate of nocturnal hypoglycemic events in the ASPIRE In-Home study. Poster presented at EASD 2014: 50th Annual Meeting of the European Association for the Study of Diabetes, 15-19 September 2014, Vienna, Austria. Abstract to be published in Diabetologia.

Timothy S. Bailey, James Thrasher, Frank L. Schwartz, David C. Klonoff, Ram Weiss, Meng Mao, ASPIRE In-Home Study Group. Predictors of Nocturnal Hypoglycemia in Patients with Type 1 Diabetes – Effects of Automatic Threshold Suspend Feature Activation. Poster presented at DTS 2014: Diabetes Technology Society, Bethesda, MD, November 6-8, 2014.

Thrasher J, Bhargava A, Wang T, Guzman C, Glass L. Using Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro versus Insulin Aspart. Endocrine Practice March 2015.

Thrasher J, Kountz D, Crowe S, von Eynatten M, Wooddell, M. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes (T2D): Pooled Analysis from Eight Randomized, Placebo Controlled Phase 3 Trials. Postgraduate Medicine. Jun 2015;127(5):419-28.

Mazen Alsahi, MD, James R. Thrasher, MD, John E. Gerich, MD. Hypoglycemia with New Generation Basal Analog Insulins: A Descriptive Critical Review. Journal of Diabetes & Metabolism 6(8):576.

Ram Weiss, MD, PhD, Satish Garg, MD, David C. Klonoff, MD, Timothy S. Bailey, MD, Frank Schwartz, MD, James Thrasher, MD, John B. Welsh, MD, PhD, Francine R. Kaufman, MD, ASPIRE In-Home Study Group. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. Journal of Diabetes Science and Technology. 2015 May 18;9(5):1016-20.

Weiss R., Bode B., Bailey T., Schwartz F., Brazg R., Bergenstal R., Thrasher J., Weinstock R., Ahmann A., Klonoff D., Slover R., Garg S., Welsh J., Mao M. Effects of automatic insulin pump interruption on duration and weekly rate of nocturnal hypoglycaemic events in the ASPIRE In-Home Study
Diabetologia 2014 57:1 SUPPL. 1 (S412-)

Weiss R., Slover R.H., Schwartz F.L., Thrasher J., Welsh J.B., Mao M., Kaufman F.R. Effects of automatic insulin pump interruption on the timing and rate of nocturnal hypoglycemic events in the ASPIRE in-home study. Pediatric Diabetes 2014 15 SUPPL. 19 (48-)

Klonoff D., Ahmann A., Garg S., Slover R., Bailey T., Bode B., Thrasher J., Brazg R., Schwartz F., Mao M., Weiss R. Effects of automatic insulin pump interruption and bedtime glucose levels on nocturnal hypoglycaemic events in the ASPIRE In-Home Study.
Diabetologia 2014 57:1 SUPPL. 1 (S266-S267)

Weinstock R.S., Bergenstal R.M., Garg S., Bailey T.S., Thrasher J., Mao M., Shin J. Reduction in hypoglycemia across a range of definitions in the aspire in-home study Diabetes 2014 63 SUPPL. 1 (A240-)

Weiss R., Bailey T.S., Schwartz F.L., Garg S., Ahmann A.J., Thrasher J., Huang S., Lee S.W. Time spent (%) in hypoglycemia following automatic threshold suspend activation in the aspire in-home study. Diabetes 2014 63 SUPPL. 1 (A241-)

Thrasher, James. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Medicine. 130. . 10.1016/j.amjmed.2017.04.004.

Thrasher, James. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Cardiology. 120. . 10.1016/j.amjcard.2017.05.009.

James Thrasher, MD, Howard Surks, MD, Irene Nowotny, PhD, Suzanne Pierre, MSc, Baerbel Rotthaeuser, PhD, Karin Wernicke-Panten, MD, Satish Garg, MD Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. Journal of Diabetes Science and Technology, Article first published online ahead of print: 23 Jan 2018. https://doi.org/10.1177/1932296817753644

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomized, placebo-controlled trial. Lancet Diabetes Endocrinol. Article first published online ahead of print: Mar 1, 2019. https://doi.org/10.1016/S2213-8587(19)30066-X

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Lancet. 2019 Jun 7. pii: S0140-6736(19)31149-3. doi: 10.1016/S0140-6736(19)31149-3. [Epub ahead of print]

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Lancet. 2019 Jun 7. pii: S0140-6736(19)31150-X. doi: 10.1016/S0140-6736(19)31150-X. [Epub ahead of print]

BERNARD ZINMAN, VAISHALI BHOSEKAR, ROBERT S. BUSCH, INGRID HOLST, BERNHARD LUDVIK, JAMES THRASHER, VINCENT C. WOO and ATHENA PHILIS-TSIMIKAS. Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9. Diabetes 2019 Jun; 68 (Supplement 1): 986-P. https://doi.org/10.2337/db19-986-P

JAMES THRASHER, SARIT POLSKY, LIONEL HOVSEPIAN, IRENE K. NOWOTNY, BéATRICE BOIS DE FER, ANUJ BHARGAVA, SATISH K. GARG Safety Assessment of SAR341402 and NovoLog When Administered through an Insulin Pump. Diabetes Jun 2019, 68 (Supplement 1) 137-LB; DOI: 10.2337/db19-137-LB

Dr. James Thasher, Prof. Sarit Polsky, Dr. Lionel Hovsepian, Dr. Irene Nowotny, Dr. Suzanne Pierre, Ms. Béatrice Bois De Fer, Anuj Bhargava, Dr. Bhaswati Mukherjee, and Prof. Satish K Garg. Safety and tolerability of insulin aspart biosimilar SAR341402 versus originator insulin aspart (NovoLog®) when used in insulin pumps in adults with type 1 diabetes: A randomized, open-label clinical trial. Journal of Diabetes Science and Technology Published Online:13 Dec 2019. https://doi.org/10.1089/dia.2019.0446

Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in Subjects with T1D. Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-97-LB

RESEARCH AS PRINCIPAL INVESTIGATOR

"An 8 week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskarin (150mg

and 300mg) administered alone and in combination with valsartan (160mg and 320mg) in patients with hypertension", Phase III, Novartis Pharmaceuticals

"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential-Design Study to Evaluate the Lipid-Altering Efficacy and Tolerability of MK-0354 in Patients with Dyslipidemia", Phase IIa, Merck & Co., Inc.

"Impact of a Self-Adjusted Titration Guideline in Subjects with Type 2 Diabetes Mellitus: A 6-Month, Multicenter, Open-Label, Randomized, Parallel-Group, Treat-to-Target of the Efficacy and Safety of Detamir" Phase IV, Novo Nordisk Pharmaceuticals.

"Glycemic Optimization Trial (GOT): To Assess The Safety Of Glucose Control As Measured By The Frequency Of Severe Hypoglycemia Events Using Dosing Algorithms Based On Different Fasting Blood Glucose Goals with Lantus (Insulin Glargine [rDNA Origin]) In Adult Individuals With Type 2 Diabetes Who Have Not Achieved The Target A_{1c} of <7% With Oral Hypoglycemia Agents: A Randomized, Open-Label, Parallel-Design Trial", Phase IV, Aventis Pharmaceuticals

TREAT "Trial to Reduce Cardiovascular Events with Aranesp Therapy", Phase III, Amgen Inc.

"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of YM 443 in Subjects with Functional Dyspepsia, Phase IIb, Yamanouchi Pharma America, Inc.

"A multi-center, randomized, double-blind, placebo controlled study of the effect of SSR180575 at two doses for 24 weeks treatment on the rate of regeneration of epidermal nerve fibers in patients with mild diabetic peripheral neuropathy." Phase II, Sanofi-Aventis.

"An Open-Label, Single-arm Study to Assess the Safety of Aranesp Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease", Phase III Amgen Inc.

"A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist Avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy." Phase III, Speedel Pharma Ltd.

"A randomized, double blind, placebo-controlled, parallel-group, multicentered study to assess the efficacy and safety of long-term administration of Rimonabant in the prevention of type 2 diabetes in patients with prediabetic status." Phase III, Sanofi-Aventis.

"A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with fixed combination therapy of Vildagliptin and metformin to

the individual monotherapy components in drug naïve patients with type 2 diabetes" Phase III, Novartis Pharmaceuticals.

"All To Target Trial Lantus® (insulin glargine) with stepwise addition of APIDRA® (insulin glulisine or Lantus with one injection of Apidra vs. a twice-daily premixed insulin regimen (Novolog® Mix 70/30™) in adult subjects with type 2 diabetes failing dual or triple therapy with oral agents: a 64-week, multi-center, randomized, parallel, open-label clinical study," Phase IV, Sanofi-Aventis.

"An 8 week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliksiren HCTZ versus Amlodipine in African American Patients with Stage 2 Hypertension" Phase IV, Novartis Pharmaceuticals.

"An 8-week Randomized , Double-Blind, Active Control, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskinin HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients with Stage 2 Systolic Hypertension" Phase IV, Novartis Pharmaceuticals.

"A Double Blind, Active-Controlled, Long term, Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Three or more Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine" Phase IV, Gilead Sciences, Inc.

" A Double-Blind, Placebo- and Active-Controlled, Mulit-Center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or more Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine" Phase III, Gilead Sciences, Inc.

"A Multi-center Randomized, Double-Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate versus Aggressive Treatment Regimen on Exforge in Patients Uncontrolled on ARB Monotherapy" Phase III, Novartis Pharmaceuticals.

"An 8 Week Randomized, Double-Blind, Parallel-Group, Multicenter, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25mg) Compared to Amlodipine (10 mg) in Patients with Stage 2 Systolic Hypertension and Diabetes Mellitus" Phase IV, Novartis Pharmaceuticals.

"A Multi-center, Randomized, Double –blind Study to Evaluate the Efficacy and Long-term Safety of Vildagliptin Modified Release (MR) as Monotherapy in Patients with Type 2 Diabetes" Phase II/III, Novartis Pharmaceuticals.

"A Randomized, Observer-blind, Active-controlled Study to Demonstrate the Superior Efficacy of GSK Biologicals Adjuvanted Influenza Vaccine GSK2186877A Administered Intramuscularly in Elderly Aged 65 or Above as Compared to Fluarix TM" Phase III, Glaxo, Smith, Kline Pharmaceuticals.

"A 12-week multicenter, randomized, double-blind, parallel group, active-control study to evaluate the antihypertensive efficacy and safety of an Exforge® (valsartan/amlodipine)-based regimen versus a losartan based regimen in patients with Stage 2 systolic hypertension," Phase III, Novartis Pharmaceuticals.

"A multicenter, randomized, double blind, parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen of Exforge in patients uncontrolled on ARB monotherapy," Phase II/III, Novartis Pharmaceuticals.

"An 8 week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination with Aliskiren (160/150 mg, 320/300 mg) versus Valsartan alone (160 mg, 320 mg) in Patients with Stage 2 Hypertension," Phase III, Novartis Pharmaceuticals.

"An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination with Amlodipine (150/5 mg, 300/10 mg) versus Amlodipine alone (5 mg, 10 mg) in African American Patients with Stage 2 Hypertension," Phase III, Novartis Pharmaceuticals.

"A 12-week multi-center, randomized, double-blind, placebo controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetes," Phase II, Novartis Pharmaceuticals.

"A multi-center, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus sitagliptin (25 mg qd) in patients with type 2 diabetes and severe renal insufficiency," Phase IIIb, Novartis Pharmaceuticals.

"A 28 week extension to a 24 week multi-center, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability of vildagliptin 50 mg qd versus sitagliptin 25 mg qd in patients with type 2 diabetes and severe renal insufficiency," Phase IIIb, Novartis Pharmaceuticals.

"A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly subcutaneous Indrabiotaparinux (SSR126517E) with Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients Events in Patients with Atrial Fibrillation", Phase III, Sanofi-Aventis.

"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction," Phase III, Novartis Pharmaceuticals.
"A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction, " Phase III, Novartis Pharmaceuticals.

"A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin," Phase II, Sanofi-Aventis.

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Cardiovascular Outcomes during Treatment with Lixisenatide in Type 2 Diabetic Patients after an Acute Coronary Syndrome," Phase III, Sanofi-Aventis.

"A Long-term, Multi-centre, International, Randomised, Double-Blind, Placebo-controlled Trial to Determine Liragulitide Effects on Cardiovascular Events," Phase III, Novo Nordisk.

"A Phase IIIb, 24-week, randomized, placebo-controlled, double-blinded, efficacy and safety study of linagliptin in Black/African American patients with type 2 diabetes with a MTT sub-study," Phase IIIb, Boehringer Ingelheim.

"An open label randomized multicenter study to assess patient preference for and evaluate clinical benefit of insulin glargine (Lantus®) SoloSTAR® pen versus conventional vial/syringe method of insulin glargine (Lantus®) injection therapy in patients with type 2 diabetes mellitus," Phase IV, Sanofi-Aventis.

"A mulitcentre, internationational, randomized, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial," Phase III. Boehringer Ingelheim.

"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of BI10773 25 mg/linagliptin 5 mg and BI 10773 10 mg/linagliptin 5 mg Fixed Dose Combination tablets compared with the individual components (BI 10773 25 mg, BI 10773 10 mg, and linagliptin 5 mg) for 52 weeks in treatment naïve and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control." Phase III, Boehringer Ingelheim,

"Protocol H9X-MC-GBDJ (REWIND). The Effect of LY2189265 on Major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)". Phase III,Eli Lilly and Co.

"A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ration combination versus insulin glargine on top of metformin in type 2 diabetic patients." Phase III, Sanofi-Aventis.

"Protocol F3Z-MC-IOQH(a). A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro with the Safety and Efficacy of Insulin Aspart in Subjects with Type 2 Diabetes on CSII Therapy." Phase IIIb, Eli Lillly and Co.

"EFC11628, 6-month, Multicenter, Randomized, Open-label, Parallel group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period." Phase III, Sanofi-Aventis.

"EFC11629, 6-month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both in combination with oral antihyperglycemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period." Phase III, Sanofi-Aventis.

"ACT12374, A Randomized, 24-Week, Open-Label, 2-arm Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-Ratio Combination Versus Insulin Glargine on top of Metformin in Type 2 Diabetic Patients." Phase III, Sanofi.

CEP237/Z25/G "ASPIRE (Automation to Simulate Pancreatic Insulin Response): Pivotal In Home Study to determine Safety and Efficacy of the LGS Feature in Sensor-Augmented Pumps." Medtronic Diabetes

"Protocol 12R-MC-BIAM. The impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus with Insulin Lispro: a Double-Blind Randomized, 26-Week Study. The IMAGINE 4 Study" Phase III, Eli Lilly and Co.

"Protocol MB102077. A multicenter, Randomized, Double-Blind, Placebo controlled, Parallel Group, Phase 3 Trial to Evaluate the safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes and inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication.", Phase III, BMS.

"Protocol MB102073. A multicenter, Randomized, Double-Blind, Placebo controlled, Parallel Group, Phase 3 Trial to Evaluate the safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes and inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)." , Phase III, BMS.

"Protocol B1261007-A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF04634817) in Adults with Type 2 Diabetes and Overt Nephropathy." Pfizer.

"BMS CV:181169: A Mulitcenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin compared to Add-On Therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects with Type 2 Diabetes who have inadequate Glycemic Control on Metformin Alone." Bristol-Meyers Squibb.

"AVE0010-EFC12626 GETGOAL DUO-2 A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week study comparing the Efficacy and Safety of Lixisenatide to that of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients with Type 2 Diabetes Insufficiently Controlled with Insulin Glargine with or without Metformin." Sanofi.

"EFC12347 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs with a 6-month Safety Period." Sanofi.

"EFC12456 A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period." Sanofi.

"Protocol IBHC-Two Treatment Approaches for Humulin Regular U-500 Insulin (Thrice-Daily versus Twice-Daily) in Subjects with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy with or without Oral Agent: A Randomized, Open-Label, Parallel Clinical Trial. Eli Lilly and Co.

"CV181169 A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On therapy with Saxagliptin and Dapagliflozin added to Metformin compared to Add-On Therapy with Saxagliptin win combination with Metformin or Dapagliflozin in combination with

Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone." Bristol-Myers Squibb.

"CEP266/Z25/B-EDMS A post Approval Study of the TS (Threshold Suspend) Feature with a Sensor-Augmented Pump System. " Medtronic Diabetes

"EX1250-4080 A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events" Novo Nordisk

"NN9211-3919 The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes." Novo Nordisk

"NN9211-4083 The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes: A 26-weeks randomised insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-centre trial." Novo Nordisk

"28431754DIA4004 A randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subects with Type 2 Diabetes Mellitus with inadequate Glycemic Control on Metformin and Sitagliptin Therapy." Janssen

"28431754DIA2004 A randomized, Phase 2, Double-blind, Placebo Controlled, Treat-to-target, Parallel-group, 3-arm, Multicenter Study to assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to insulin in the treatment of Subjects with Type 1 Diabetes Mellitus" Janssen

"EFC12405 A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination to insulin glargine with or without metformin in patients with T2DM." Sanofi

"EFC12404 A randomized, 30-week, active-controlled, open label, 3-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus." Sanofi

"EFC13403 Six month, randomized, open-label comarison of the insulin analog SAR342432 to Humalog in adult patients with type 2 diabetes mellitus also using inslin glargine" Sanofi

"PDY13502 A Randomzied, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study assessing the safety of SAR342434 and Humalog used in continuous subcutaneous insulin infustion (CSII) in adult patients with type I diabetes mellitus (T1DM)" Sanofi

"MB102229 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 study to evaluate the efficacy and safety of Dapagliflozin as an Add-on to insulin therapy in subjects with Type I Diabetes Mellitus" AstraZeneca AB (Study being conducted by Bristol-Myers Squibb on behalf of AstraZeneca AB)

"LX4211.1-1-309-T1DM A Phase 3, Ranomized, Double-blind, Placebo controlled, Parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type I Diabetes Mellitus Who Have Inadequate Glycemic Control with Insulin Therapy" Lexicon Pharmacueticals, Inc.

"LPS14354 A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy" Sanofi

"LPS 14587 A Randomized, Active-Controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients with Type 1 Diabetes Mellitus" Sanofi

"NN9924-4221 PIONEER 6 – Cardiovascular outcomes. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.

"EFC15081 Gemelli 1-Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to Novolog®/NovoRapid® in Adult Patients with Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period" Sanofi

"NN9535-4269 SUSTAIN9-Add-on to SGLT-2i; Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as Add-on to SGLT-2i in Subject with Type 2 Diabetes Mellitus" Novo Nordisk

"EFC14837 SOTA-CKD3-A Randomized, Double-blind, Placebo Controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control" Sanofi

"EFC15166 SOTA-CKD4- A Randomized, Double-blind, Placebo Controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Severe Renal Impairment who have Inadequate Glycemic Control" Sanofi

"EFC14838 SOTA-GLIM- A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo controlled, Parallel group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Glimepiride or Placebo Added to Metformin in Patients with Type 2 Diabetes who have Inadequate Glycemic Control with Metformin Monotherapy" Sanofi

"PDY15083 GEMELLI P- A Randomized, Double-blind, Controlled, Single-dose, 3-treatment, 3-period, 6-sequence, Crossover Study to Compare Exposure and Activity of SAR341402 to NovoRapid and NovoLog® Using the Euglycemic ClampTechnique, in Patients with Type 1 Diabetes Mellitus" Sanofi

"EX9924-4473 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL). Semaglutide Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes" Novo Nordisk

"MYL-1601D-3001 Mylan Insulin Aspart Study. A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601-D with Novolog in Type 1 Diabetes Mellitus Patients" Mylan

"CIP321 Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System. Adult and Pediatric Trials". Medtronic Diabetes

"CEP298 Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes". Medtronic Diabetes

"F3Z-MC-IOQY User Experience and Daily Use Patterns with the Integrated Insulin Management (IIM) System Study". Eli Lilly

"CIP331 Use of the Guardian™ Connect System With Smart Connected Devices". Medtronic Diabetes

Sub-Investigator
Intravenous Antibiotic in Complicated Lower Urinary Tract Infection, Phase II

Speaker Bureau (*current)
Medtronic (National and International)*
Sanofi *
Novo Nordisk
Eli Lilly (International)*
Amylin
Bristol-Myers Squibb
Boehringer Ingelheim
Vivus
Astra Zeneca *
Daiichi-Sankyo
Takeda
GlaxoSmithKline
Janssen

Advisory Board
Senseonics
Sanofi-Aventis
Medtronic
Pfizer Pharmaceuticals
Novo Nordisk

Consultant
Boehringer Ingelheim
Eli Lilly
Medtronic
Sensionics
Novo Nordisk

Data Safety Monitoring Board
Board Member 2013-Present. Medtronic Diabetes (closed-loop technology studies)

14th International Conference on Advanced Technologies &Treatments for Diabetes
March 3, 2021 Introducing Tempo: A Connected Insulin Pen to Simplify Diabetes Management - Industry Symposium Supported by Eli Lilly
"Introducing Tempo and Insulin Dosing Data for More Informed Treatment Conversations". James Thrasher, United States

American Association of Clinical Endocrinologists 21st Annual Meeting and Clinical Congress
May 24, 2012 Oral Presentation – "Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-Month, Randomized, Double-Blind, Placebo-Controlled Study". James Thrasher

Guest Speaker
Taking Control of Your Diabetes
Little Rock, AR Oct 2007

Clinical Trial Investigator Meetings
Speaker, TREAT Trial, Amgen, Los Angeles, CA.
Speaker and Expert Panel, ELIXA Trial, Sanofi, Miami, FL, Scottsdale, AZ.
Speaker and Breakout Session Moderator, Sorella-2 Investigator Meeting, Sanofi Miami Beach, FL Feb 25-27, 2015

Keynote Speaker. *Insulin Pump Therapy: Expert Program*, Medtronic Diabetes USA
Hilton Dallas/Southlake Town Square, Dallas, TX Jan 20-21, 2012
Hyatt Regency La Jolla at Aventine, San Diego, CA, Aug 24, 2012
New Orleans Marriott, New Orleans, LA, Sep 7-8, 2012
Renaissance Tampa International Hotel, Tampa, FL, Jul 13-14, 2012
Denver Marriott City Center Denver, CO, Nov 8-9, 2012
Green Valley Ranch Resort, Las Vegas, NM, Feb 1-2, 2013

Roosevelt Hotel, New Orleans, LA, Feb 15-16, 2013
W Atlanta – Buckhead, Atlanta, GA, March 22-23, 2013
Renaissance Denver Hotel - Marriott, Denver, CO, Jul 12-13. 2013
Westin New Orleans Canal Place, New Orleans, LA, June 20-21, 2014.
Marriott Charlotte City Center. Charlotte, NC, March 6-7, 2015
JW Marriott Hotel. Indianapolis, IN June 19-20, 2015
Gaylord Palms Resort & Convention Center, Kissimmee, FL, Aug 19-20, 2016
Gaylord Opryland Resort & Convention Center, Nashville, TN, Oct 21-22, 2016
Renaissance Blackstone Chicago Hotel, IL, Aug 11-12, 2017.
New Orleans Marriott Downtown Convention Center New Orleans, LA, Jan 19-20, 2018

Keynote Speaker. ***Insulin Pump Therapy: Expert Program,*** **Medtronic Canada**
Westin Bristol Place. Toronto, Ontario, Sep 17-19, 2015
Pacific Gateway Hotel. Vancouver, British Columbia, Nov 5-7, 2015
Hilton Mississauga/Meadowvale, Greater Toronto Area, Ontario, Jan 8-9, 2016
Halifax Marriott Harbourfront Hotel, Halifax, Nova Scotia, Feb 27-28, 2016
Sheraton Suites Calgary Eau Claire. Calgary, Alberta, March 3-4, 2016
"Clinical evidence and medically relevant aspects of insulin pump therapy and continuous glucose monitoring, including presenting ASPIRE data and aggregate data related to VEO and CGM". Live-streamed video broadcast to Medtronic Canada conferenced healthcare education program. Toronto, Ontario. March 21, 2016

Keynote Speaker. ***CGM Therapy: Expert Program,*** **Medtronic Diabetes USA**
Warner Center Marriott Woodland Hills, Los Angeles, CA, Apr 4-5, 2013
Warner Center Marriott Woodland Hills, Los Angeles, CA, May 9-10, 2013
Warner Center Marriott Woodland Hills, Los Angeles, CA, Jun 6-7, 2013
The Palomar Hotel Westwood, Los Angeles, CA, Aug 1-2, 2013
The Palomar Hotel Westwood, Los Angeles, CA, Sept 5-6, 2013
Medtronic Headquarters Northridge, Los Angeles, CA, January 30-31, 2014
Medtronic Headquarters Northridge, Los Angeles, CA, June 20-21, 2014
The Drake Hotel, Chicago, IL, Jul 11-12, 2014
Tampa Marriott Westshore, Tampa FL, Oct 16-17, 2015
Seattle Marriott Bellevue, Seattle, WA, Feb 19-20, 2016
Medtronic Headquarters Northridge, Los Angeles, CA, Mar 17-18, 2016
Medtronic Headquarters Northridge, Los Angeles, CA, Jun 23-24, 2016
Medtronic Headquarters Northridge, Los Angeles, CA, Sep 8-9, 2016
Medtronic Headquarters Northridge, Los Angeles, CA, Jan 19-20, 2017
Medtronic Headquarters Northridge, Los Angeles, CA, Feb 16-17, 2017
Medtronic Headquarters Northridge, Los Angeles, CA, Jun 22-23, 2017
Medtronic Headquarters Northridge, Los Angeles, CA, Jul 20-21, 2017
Medtronic Headquarters Northridge, Los Angeles, CA, Sep 6-7, 2018

Keynote Speaker. ***Hybrid Closed Loop: Expert Program,*** **Medtronic Diabetes USA**
Medtronic Headquarters Northridge, Los Angeles, CA, Oct 4-5, 2018
Medtronic Headquarters Northridge, Los Angeles, CA, Nov 1-2, 2018

Medtronic Headquarters Northridge, Los Angeles, CA, Jan 31- Feb 1, 2019
Medtronic Headquarters Northridge, Los Angeles, CA, May 16-17, 2019
Medtronic Headquarters Northridge, Los Angeles, CA, Jan 8-9, 2020

Keynote Speaker and Speaker Trainer. ***CGM Therapy and Insulin Pump Therapy: Speaker Training Program*****, Medtronic Diabetes USA**
The Palomar Hotel, Los Angeles, CA, Jul 25-26, 2013

Keynote Speaker and Speaker Trainer. ***Train the Trainer Program*****, Medtronic Canada**
The Palomar Hotel, Los Angeles, CA, 21 Oct 2017

Speaker Trainer. ***Medtronic Type 2 Speaker Training Sessions.***
February 7th, 13th, and 15th, 2018

Guest Speaker. ***Medtronic Diabetes's National Sales Meeting*****.** Fort Lauderdale, Florida, May 17-20, 2015

Guest Speaker: Legendary Leadership. ***Medtronic Diabetes's Leadership of Americas Meeting*****.** Las Vegas, Nevada, May 22, 2019

Panel Discussion. Medtronic Marketing Summit. Virtual March 4, 2021

Signature_____
Date _____